AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06495853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Circumferential Reinforcement of the Anastomotic
Description: The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.
Study NCT04341701 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
Study NCT06443775 — intervention group
Intervention type: DRUG
Intervention: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Description: Eye Drops
Study NCT06536127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Nk cells and ImmunoScore
Study NCT05750290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-702 in combination with irinotecan
Description: CKD-702 and irinotecan will be intravenously administered every 2 weeks.
Study NCT05786248 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Impedancemetry
Description: the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
Study NCT04947462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronically Implanted Neural and Muscular Interface
Description: Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
Study NCT06423846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia group
Description: Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1 ug/kg/hour
Study NCT06423846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane group
Description: For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
Study NCT06575829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks
Description: The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
Study NCT01085851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% lotion
Description: Small amount applied over the lesion twice a day for 7 days
Study NCT01085851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% cream
Description: Small amount applied over the lesion twice a day for 7 days
Study NCT05973110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
Study NCT05973110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
Study NCT05488392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia with intrajugular cooling
Description: Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
Study NCT05173259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
Study NCT06575101 — intervention group
Intervention type: PROCEDURE
Intervention: Target Temperature Management Treatment
Description: Target Temperature Management Treatment
Study NCT06495476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba extract 50 dropping pills
Description: Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.
Study NCT06495476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant
Description: Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance.~Size: 10 mg analog ingredient/pill.
Study NCT06211205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized 3D printed nostril retainer combined with lip taping
Description: the infants will receive a customised nostril retainer appliance to enhance the nasal esthetics combined with lip tape to approximate the labial and alveolar segments
Study NCT06211205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lip taping
Description: the infants will receive lip tape to approximate the labial and alveolar segments
Study NCT05596370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA in blood and urine, metabolite/microbiome in urine and stool
Description: cell free DNA in blood and urine, metabolite/microbiome in urine and stool
Study NCT06237205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: a highly selective PARP1 and PARP2 inhibitor
Study NCT05173259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
Study NCT05173259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
Study NCT05024578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DREEM2
Description: Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
Study NCT05024578 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
Study NCT05182671 — intervention group
Intervention type: OTHER
Intervention: Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion
Description: Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:
Study NCT04938245 — intervention group
Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above.
Study NCT06533228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)
Description: Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.
Study NCT06315556 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea)
Description: Eylea 40 mg/mL solution for injection in pre-filled syringe.
Study NCT06395662 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Search for biomarkers
Study NCT04791449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
Study NCT06574490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy (+)
Description: A series of myofunctional exercises performed in 10-20 sessions over 6 months
Study NCT06574490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofunctional therapy (-)
Description: NO exercises; A series of myofunctional exercises performed in 10-20 sessions over 6 months is delayed by 1 year
Study NCT03945955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
Study NCT03945955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05589688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
Study NCT04917523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Description: 0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
Study NCT06329349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks, 3 times a week of progressive endurance aerobic exercise (150 to 400kcal AEE per session)
Study NCT06329349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise + Diet
Description: 12 weeks, 25% caloric reduction, based on PMID: 37069434
Study NCT05170048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-301
Description: The investigation drug, EG-301 Tablets 150mg, is for oral use.
Study NCT05170048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AREDS2 supplements
Description: AREDS2 supplement is the stand of care
Study NCT05170048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AREDS2 supplements
Description: AREDS2 supplement is the stand of care
Study NCT04917523 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Description: 0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
Study NCT04593433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Museum virtual guided tours
Description: The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
Study NCT05738057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg on day1 of every 3 weeks, starting on day1 of cycle1
Study NCT05738057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: 1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
Study NCT05738057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: 25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
Study NCT05738057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-Eluting Beads
Description: used for D-TACE
Study NCT05931692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual reality
Description: Virtual environment that triggers fear of falling
Study NCT05931692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram
Description: Detect brain waves in response to fear of falling
Study NCT05931692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Measures muscle activity and response to fear of falling
Study NCT05931692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Capture system
Description: Measures postural and gait responses to fear of falling
Study NCT05931692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polar H10 Heart Sensor
Description: Heart rate monitor
Study NCT05931692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial measurement Unite
Description: Measure Postural sway
Study NCT05667220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
Study NCT05667220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin combined with Beidougen capsule
Description: Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
Study NCT06034587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal ultrasound
Description: An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
Study NCT06034587 — intervention group
Intervention type: RADIATION
Intervention: radioisotope applicator therapy
Description: The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
Study NCT06106386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Cooling of irrigation
Study NCT06106386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Cooling of irrigation
Study NCT05738057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D-TACE
Description: TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
Study NCT05090579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I (BN10)
Description: patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
Study NCT05090579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Group ll (BN20)
Description: patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
Study NCT05090579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Group lll (B)
Description: patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
Study NCT06580691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads
Description: Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision.
Study NCT04592770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature based walk therapy
Description: 10 minutes stretching exercises followed by walk in nature for 50 minutes
Study NCT04592770 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sit in nature
Description: Sit in nature for 60 minutes
Study NCT06196229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation Therapy
Description: During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks
Study NCT06196229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy combined with Virtual Reality
Description: In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions
Study NCT04557865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PMPBB3 (APN-1607) PET imaging
Description: 1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical
Study NCT06646185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Pads
Description: Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
Study NCT05054374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously
Study NCT05054374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant
Study NCT06215950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically